Purpose Lung cancer is a leading cause of cancer deaths and efforts are underway to identify novel therapies to treat these tumors. Diacylglycerol kinase g (DGKg), an enzyme that phosphorylates diacylglycerol to form phosphatidic acid, has been shown to modulate MAPK signaling downstream of EGFR, which is an oncogenic driver in some lung cancers. Since mutations in EGFR and K-Ras are common in lung cancer, we hypothesized that limiting the function of DGKg would attenuate oncogenic properties of lung cancer cells. Methods We determined the expression levels of DGKg in a mouse models of mutant EGFR and K-Ras lung cancer and in human lung cancer cell lines with activating mutations in either EGFR or K-Ras. We also tested the effects of shRNA-mediated depletion of DGKg in lung cancer cells and tested if DGKg depletion augmented the effects of afatinib, a new generation EGFR inhibitor. Results DGKg was expressed in malignant epithelium from mice with mutant EGFR or K-Ras lung cancer. It was also expressed in human lung cancer cell lines with EGFR or K-Ras mutations. Depleting DGKg in lung cancer cell lines, harboring mutant EGFR, reduced their growth on plastic and in soft agar and also augmented the effects of afatinib, an EGFR inhibitor. DGKg depletion also reduced growth of one of two lung cancer cell lines that harbored mutant K-Ras. Conclusions Our data indicate that DGKg is a potential therapeutic target in lung cancers, especially those harboring EGFR mutations. Our findings warrant further studies to examine the effects of limiting its function in vivo.
Introduction
Lung cancer is the leading cause of cancer deaths worldwide. Much of this disease is due to tobacco smoking, but globally up to 15 % of lung cancers in men and almost half of them in women are not attributable to smoking [1] .
Often, lung cancers in never smokers harbor specific mutations in genes that are important for tumor maintenance and growth. One gene that is mutated in almost 60 % of lung cancers in never smokers is EGFR [2] . These mutations in EGFR, such as the L858R mutation, increase its kinase activity, leading to a state of oncogene addiction. As such, about 75 % of tumors harboring mutant EGFR respond to small molecule EGFR kinase inhibitors [2] , which are superior to chemotherapy as initial treatment for these tumors [3] [4] [5] [6] [7] . Unfortunately, most patients eventually develop resistance to them by a variety of mechanisms [8] [9] [10] . This has led to additional efforts to find other signaling pathways that are important for tumorigenesis promoted by mutant EGFR.
Diacylglycerol kinases, which phosphorylate the lipid second messenger diacylglycerol to form phosphatidic acid, have been shown to mediate signaling downstream of EGFR. DGKd, for example, modulates EGFR abundance and degradation by mediating its de-ubiquitination [11] . DGKg also modulates signaling downstream of EGFR by facilitating heterodimerization of B-Raf and C-Raf [12] . Both of these Raf isoforms bind to DGKg, which promotes their recruitment to the plasma membrane where they activate the MEK-ERK signaling cascade. RNAi-mediated knockdown of DGKg in HeLa cells limited proliferation by about 30 % and reduced EGF-mediated phosphorylation of both MEK and ERK [12] . Collectively, these data indicated that DGKg might be a novel cancer target downstream of EGFR or K-Ras, so we set out to determine the effects of limiting its function in lung cancer cell lines that harbor activating mutations in EGFR or K-Ras.
Materials and methods
Cell lines, expression plasmids, cell culture, and transfection All cell lines (H441, H460, H1650, and H1975) were from American Type Culture Collection and propagated in RPMI 1640 (Invitrogen) with 10 % FBS and antibiotics. The type of lung cancers from which these cells were derived as well as their EGFR and K-Ras mutation status are indicated in Fig. 1a AD AD AD LC Fig. 1 Expression of DGKg in lung cancer cell lines and in a mouse model of mutant EGFR lung cancer. a Lung cancer cell lines were grown to confluence, harvested, and then the levels of DGKg and actin were detected in the cell lysates by Western blotting. The mutation status of EGFR or K-Ras in each cell line is shown below the blot (mut mutation, wt wild-type). The type of lung carcinoma from which each line was obtained is also indicated (AD adenocarcinoma, LC large cell carcinoma). b Lungs from rtTA(-) 9 EGFR-L858R (control) or rtTA(?) 9 EGFR-L858R (L858R) mice treated with doxycycline for 8 weeks were harvested, fixed, sectioned, and stained with eosin. c Lung sections from control or L858R mice were immunostained to detect EGFR, PCNA, or DGKg proliferation was assessed by plating 10,000 cells in a 10-cm diameter plate, growing them in 1 % FBS with antibiotics for 5-7 days, and then counting the number of cells. Growth in soft agar was performed as described [13] .
Reverse transcription polymerase chain reaction Total RNA was prepared from H1650 stable cell lines using Trizol reagent (Invitrogen) and reverse transcribed as described [14] . RT-PCR using 10 ng of total cDNA was performed with the following primers: DGKg: 5 0 -GG ACCTCCAGAAGCATCTG-3 0 (forward) and 5 0 -AACGTC ATCCCCAAGCTGC-3 0 ; actin: 5 0 -AGGCACCAGGGCG TGAT-3 0 (forward) and 5 0 -TCGTCCCAGTTGGTGACG AT-3 0 .
Western blotting
Western blotting was performed according to instructions provided by the suppliers. Anti-EGFR (#2232) antibodies were from Cell Signaling Technologies. Anti-actin (#691001) was from MP Biomedicals. Anti-DGKg (#13873-1-AP) was from Proteintech Group. Anti-PCNA (#2714-1) was from Epitomics.
Mice
All mouse experiments were reviewed and approved by the University of Utah Institutional Review Board. Transgenic mice expressing the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat clara cell secretory protein (CCSP) gene promoter were obtained from The Jackson Laboratory (stock#006232). L858R-EGFR transgenic mice were obtained from the NCI mouse repository (strain#01XEA). Bi-transgenic CCSP-rtTA x L858R-EGFR or control L858R-EGFR mice were given doxycycline (1gm/L) in their water for 8 weeks. Mouse lungs harboring mutant K-Ras (LSL-Kras G12D/? ) treated with or without adenoviral Cre as described [15] and harvested 12 weeks later were provided by Trudy Oliver (University of Utah).
Histological analysis
Lungs harvested from control or L858R-EGFR mice were fixed in 10 % neutral buffered formalin for 30-48 h, paraffin embedded, sectioned (5 lm), and stained with hematoxylin and eosin according to standard protocol. Immunostaining was performed using the ABC reagent (Vector Laboratories) and anti-EGFR (#1902-1) or anti-PCNA (#2714-1) from Epitomics or anti-DGKg (#13873-1-AP) from Proteintech Group according to instructions provided by the suppliers.
Results

DGKg is expressed in human lung cancer cell lines and a mouse model of mutant EGFR lung cancer
To determine if DGKg was expressed in human lung cancers, we surveyed a panel of human non-small cell lung cancer cell lines that had activating mutations in either EGFR (H1650 and H1975) or K-Ras (H441 or H460). We found that DGKg was expressed in all of them and that the levels of DGKg did not correlate with EGFR or K-Ras mutation status (Fig. 1a) . This was consistent with prior data demonstrating that the levels of DGKg mRNA were not affected by activation of EGFR [16] . To further assess the expression levels of DGKg in mutant EGFR lung tumors, we obtained bi-transgenic mice in which doxycycline induces expression of an L858R-EGFR transgene in type II lung pneumocytes [17] . In preliminary experiments, we found that doxycycline induced significant tumor load after 8 weeks of treatment (Fig. 1b) . As expected, EGFR was highly expressed in the tumors, but not in lungs of mice that were treated with doxycycline but did not carry the rtTA transgene necessary to induce expression of the L858R-EGFR transgene (Fig. 1c) . Proliferating cell nuclear antigen (PCNA), a measure of cell proliferation, was also highly expressed in tumor-bearing lungs but was not detected in normal lungs (Fig. 1c) . We found that DGKg was expressed in bronchial epithelium of control mice (Fig. 1c) and was highly expressed in malignant epithelium of L858R-EGFR mice (Fig. 1c) . Collectively, these data indicate that DGKg is expressed in human lung cancer cell lines as well as in a mouse model of EGFR mutant lung cancer. Together with its known role in modulating EGFR signaling, these data suggest that DGKg might promote tumorigenesis in EGFR or K-Ras mutant lung cancer.
Depletion of DGKg reduces oncogenic properties of lung cancer cells harboring mutant EGFR
To further investigate the potentially oncogenic role of DGKg, we knocked down DGKg in human H1650 lung cancer cells. These cells express a gain-of-function mutation (delE746-A750) in the gene encoding EGFR. Using lentivirus we generated a polyclonal H1650 cell line stably expressing shRNA targeting DGKg that resulted in a *60 % reduction in DGKg mRNA (Fig. 2a) and an *80 % reduction in DGKg protein (Fig. 2b) . To evaluate the effects of DGKg depletion on cell proliferation, we used cell counting assays and found 5 days after plating the cells in 1 % serum significantly reduced cell numbers of DGKg-deficient cells compared to control cells (Fig. 2c) . Transient depletion of DGKg using siRNA oligonucleotides targeting another region of DGKg in H1650 cells also led to a *30 % reduction in cell number 3-4 days after performing RNAi (Fig. 2d) . Together with prior results showing reduced cell proliferation of DGKg-deficient HeLa cells [12] , these data indicate that DGKg depletion leads to reduced cell number in low serum conditions.
To assess the effects of DGKg deficiency on additional oncogenic properties, we tested the growth of the stable H1650 cells in conditions of anchorage independence by growing them in soft agar and found significantly reduced colony volumes in DGKg-deficient cells compared to control H1650 cells (Fig. 3a, b) . Together with the above observations, these data indicated that depleting DGKg reduces the oncogenic potential of H1650 cells and led us to test the effects of its depletion in other EGFR mutant cell lines and to assess the potential therapeutic value of disrupting DGKg function in combination with an EGFR inhibitor.
Depletion of DGKg augments the inhibitory effects of EGFR inhibitors EGFR mutations in lung cancer can be targeted by several small molecule inhibitors that are either in clinical use or in late stage clinical trials. One of these inhibitors, afatinib (BIBW-2992), showed promising results in EGFR mutant lung cancer [18] . Since DGKg depletion reduced growth of cells harboring EGFR mutations, we tested the effects of combining afatinib with DGKg depletion. For these experiments, we generated a second cell line to test using H1975 cells, which harbor another activating EGFR mutation (L858R), to make stable DGKg knockdown cells (Fig. 4a) . In this cell line, we were only able to reduce DGKg protein by about 35 %, which was less than the *80 % reduction that we achieved in the H1650 cells.
We first tested growth of the control cell lines in the presence or absence of afatinib and in preliminary experiments we found that afatinib, alone, reduced growth of control H1650 cells more substantially than it reduced growth of control H1975 cells. This finding is consistent with the known T790 M mutation that is also harbored by H1975 cells, which reduces the affinity of EGFR for small molecule inhibitors. We then compared growth of control and DGKg-depleted cells and found in the absence of afatinib that DGKg-deficient H1975 cells proliferated more slowly than control H1975 cells (Fig. 4b) , but the reduction in proliferation caused by DGKg depletion was not as substantial as in the H1650 cells. The reduced growth inhibition in the H1975 cells might reflect the limited knockdown of DGKg that we were able to achieve compared to the H1650 cells. In both cell lines, we found that DGKg depletion combined with afatinib led to more pronounced reductions in cell counts compared to afatinib alone (Fig. 4b, c) . All differences between control and DGKg knockdown cells in the presence or absence of afatinib were statistically significant. Together, these data demonstrated that depleting DGKg reduced growth of another EGFR mutant cell line and also suggested that inhibitors of DGKg might be useful as adjuvant therapy combined with EGFR inhibitors in lung cancers harboring EGFR mutations.
DGKg depletion reduces growth of some lung cancer cell lines harboring activating mutations in K-Ras
The reduced growth of DGKg deficient cell lines was consistent with the known effects of reducing expression of DGKg in HeLa cells [12] , but the reduction of cell number was significantly greater in H1650 cells compared to the approximately 30 % reduction that was observed in HeLa cells [12] . Since HeLa cells express wild-type EGFR, the more pronounced reduction in the H1650 cells compared to HeLa cells was possibly due to the activating mutation in EGFR that the H1650 cells harbor. To further investigate the effects of DGKg deficiency on cell growth and determine if they are more pronounced in EGFR mutant cell lines, we set out to test the effects of depleting DGKg in lung cancer cell lines harboring activating mutations in K-Ras, which is mutated in about 16 % of lung cancers according to the catalog of somatic mutations in cancer (COSMIC) database. We first examined the expression levels of DGKg in a mouse model of mutant K-Ras lung cancer [15] . Similar to our observations in mutant EGFR lung tumors in mice, we found high levels of DGKg in mutant K-Ras lung tumors (Fig. 5a ), indicating that DGKg might also be important in K-Ras-driven lung tumors. DGKg and compared H460 and H441 cell lines, both of which harbor activated K-Ras, to H1650 cells. We found 3-4 days after performing RNAi and growing the cells in 1 % serum that depleting DGKg in H441 cells reduced cell number to the same extent as H1650 cells (Fig. 5b) . But DGKg depletion caused only a small, non-significant reduction in H460 cell counts (Fig. 5b) . These data indicated that the effects of DGKg depletion are not limited to cells harboring EGFR mutations. Under the conditions of these growth assays, we could not measure consistent differences in the apoptosis markers cleaved PARP or caspase-3 in control or DGKg-depleted cells (data not shown), indicating that the reduced DGKgdeficient cell numbers that we observed were likely due to changes in the levels of proliferation. To assess the level of proliferation, we assayed the abundance of PCNA and found reduced levels in DGKg-deficient H441 and H1650 cells, but not in H460 cells (Fig. 5c ). This lack of effect of DGKg depletion on PCNA levels in H460 cells was consistent with the lack of change in cell number caused by DGKg depletion. Together, these data indicate that DGKg has a prominent role in proliferation of EGFR mutant cell lines and can reduce proliferation of some cells harboring mutant K-Ras.
Discussion
Our data suggest that DGKg modulates oncogenic properties in lung cancer cells harboring EGFR mutations and in some lung cancer cells harboring K-Ras mutations.
These findings are consistent with prior studies showing that DGKg depletion also reduced HeLa cell growth [12] , indicating that DGKg modulates oncogenic properties in other types of cancer cell lines that do not harbor EGFR or K-Ras mutations. The broad effects of DGKg depletion on oncogenic behavior are not surprising given its role in facilitating Raf heterodimerization and membrane recruitment downstream of EGFR [12] . Since functional activation of EGFR is found in a majority of human epithelial cancers [19] and activating K-Ras mutations are common as well, our data indicate that DGKg is a novel cancer target and that inhibiting its function might affect a broad array of cancers.
Given the role of EGFR in lung cancer [2, 19] , we focused our efforts on understanding the effects of depleting DGKg in lung cancer cell lines. We found evidence that DGKg promotes oncogenic properties of lung cancer cells. Consistent with this conclusion, DGKg was recently identified as part of a seventeen gene microarray signature that predicted likelihood of death from non-small cell lung cancer (NSCLC) [20] . Based on the cohort used in that study, low levels of DGKg mRNA correlated with longer survival in patients with NSCLC (Ref. [20] and S. Philipsen personal communication). The favorability of reduced DGKg expression in that study is in concert with our findings that DGKg depletion reduced oncogenic properties of lung cancer cells. Given its possible role in human lung cancer, we additionally tested growth of our stable control or DGKg-deficient H1650 or H1975 cell lines as xenografts in nude mice, but we could not maintain knockdown of DGKg over the 3 weeks of the experiments. Thus, it will take a more robust knockdown system or genetic models to further study the anti-oncogenic properties of depleting DGKg in vivo.
Targeted therapies directed against EGFR have been developed and used clinically during the past few decades. They work best when used to treat tumors ''addicted'' to EGFR signaling. Unfortunately, most tumors that initially respond to the inhibitors eventually develop resistance by a variety of mechanisms [8] [9] [10] . This acquired resistance to EGFR inhibitors and the inherent EGFR inhibitor resistance of some tumors has spawned efforts to find other ways of blocking the EGFR pathway. Our data indicate that inhibiting the function of DGKg in conjunction with an EGFR inhibitor might be a viable approach to treat tumors. Indeed, we discovered that when combined with afatinib, DGKg depletion further reduced growth of both H1650 and H1975 cell lines. Collectively, our data suggest that inhibitors of DGKg might have clinical efficacy either when used alone or when combined with EGFR inhibitors.
DGKg is a type II DGK that is structurally similar to DGKd. We discovered that DGKd also modulates EGFR signaling [11, 21] and that its depletion significantly reduced proliferation of H1650 cells in both two and three dimensions (M.K.T. manuscript in preparation). As such, targeting both DGKs d and g might have additive or synergistic effects and could be a very effective therapeutic approach to limit EGFR signaling. Type II DGKs are unlike other DGK isoforms because they have a split catalytic domain [22] . This structural difference suggests that it might be possible to design inhibitors that specifically target both DGKs d and g. This possibility and the antineoplastic effects of depleting DGKg warrant further studies to examine its role in human cancer, to study the effects of depleting DGKg in animal models of lung cancer and other cancers, and to develop strategies to inhibit its tumorigenic functions.
